Related Experiment Videos
Effects of troglitazone on insulin sensitivity
1Department of Medicine, University of California, San Diego, La Jolla 92093, USA.
Diabetic Medicine : a Journal of the British Diabetic Association
|September 1, 1996
Summary
Troglitazone offers therapeutic benefits for type 2 diabetes (NIDDM) and can improve impaired glucose tolerance (IGT). This treatment reduces insulin resistance, hyperinsulinemia, and favorably impacts blood pressure, potentially preventing NIDDM development.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Insulin resistance and hyperinsulinemia are key features of obesity and impaired glucose tolerance (IGT).
- These metabolic abnormalities increase the risk of developing type 2 diabetes mellitus (NIDDM).
Purpose of the Study:
- To evaluate the therapeutic benefits of troglitazone in patients with NIDDM.
- To assess troglitazone's efficacy in normalizing IGT in individuals at high risk for NIDDM.
- To determine troglitazone's effects on insulin resistance, hyperinsulinemia, and blood pressure.
Main Methods:
- Clinical studies were conducted to assess troglitazone's effects.
- Patient outcomes related to NIDDM, IGT, insulin resistance, hyperinsulinemia, and blood pressure were monitored.
Main Results:
- Troglitazone demonstrated therapeutic benefits in patients with NIDDM.
- The drug effectively normalized IGT in at-risk individuals.
- Troglitazone treatment led to reductions in hyperinsulinemia and insulin resistance.
- Favorable effects on blood pressure were observed during troglitazone therapy.
Conclusions:
- Troglitazone is a beneficial therapeutic agent for NIDDM.
- Its ability to improve insulin sensitivity and reduce metabolic risk factors suggests a role in NIDDM prevention.
- Troglitazone may be a valuable option for managing obesity and IGT to prevent progression to NIDDM.